

## **BROCHURE**

### **6<sup>th</sup> Annual Symposium on Current Strategies in the Treatment of Hodgkins Lymphoma, B-cell Lymphoma, Multiple Myeloma and Leukemia**

**Program Director:** Fredrick Hagemester, MD, Internist and Professor of Medicine, Department of Lymphoma/Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

**July 15, 2017–Houston Marriott at the Texas Medical Center, 6580 Fannin Street, Houston, TX 77030; Phone: 713-796-0080**

#### **Jointly Provided by**

The A. Webb Roberts Center for CME of Baylor Scott & White Health, CancerNet and American Health Resource, Inc

#### **Educational Grants**

Amgen Inc.  
Merck Sharp & Dohme Corp.  
AbbVie Inc.  
Gilead Sciences Inc.  
Novartis Pharmaceuticals Corporation  
Pfizer  
Millennium Pharmaceuticals, Inc.

For online registration and more information visit: [www.cancernetus.com](http://www.cancernetus.com)

#### **Target Audience**

This symposium is directed primarily to hematologists/oncologists, radiation oncologists, researchers, pharmacists, registered nurses, physician assistants, nurse practitioners and fellows in training interested in new development in hematological malignancies such as Hodgkins lymphoma, B-cell lymphoma, multiple myeloma and leukemia. No specific skill or knowledge other than a basic training in hematology/oncology is required for successful participation in this activity.

#### **Statement of Need/Program Overview**

This symposium is intended to improve care of patients with Hodgkins lymphoma, B-cell lymphoma, multiple myeloma and leukemia by accelerating adoption of new guidelines and evidence-based practice change. The format will include didactic lectures from known opinion leaders, question and answer sessions, and ample opportunity for participant interaction with faculty.

#### **Learning Objectives**

- Evaluate the prognostic markers, risk stratification and the impact on novel therapies for Hodgkin lymphoma
- Interpret and adapt the data from recent clinical trials on immunotherapy options for Hodgkin lymphoma
- Identify the treatment options for diffuse large B-cell lymphoma (DLBCL)
- Cite the treatment options for follicular lymphoma (FL)
- Apply the treatment options for chronic lymphocytic lymphoma (CLL)
- Identify the treatment options for mantle cell lymphoma (MCL)
- Identify benefit and risks of available immunomodulatory agents, proteasome inhibitors or both as systemic therapy for patients with newly diagnosed active multiple myeloma (MM)
- Evaluate available data on the selection, sequencing and/or combination of novel therapeutic agents in the treatment of patients with relapsed/refractory MM
- Evaluate the novel therapeutic options for adolescents and young adults (AYA) relapsed/refractory Philadelphia-positive and Philadelphia-negative patients with acute lymphoblastic leukemia (ALL)

- Evaluate the gene–gene co-occurrences and how compound genotypes are related to novel therapeutic options based clinical outcomes in patients with acute myeloid leukemia (AML)
- Identify response assessment and management of tyrosine kinase inhibitors resistance in the treatment of chronic myelogenous leukemia (CML)
- Discuss the time-based response milestones and monitoring in patients with CML

**Faculty**

Jorge Cortes, MD, Professor and Chair, Department of Leukemia, Division of Cancer Medicine, The University of Texas M D Anderson Cancer Center Houston, TX

Nathan Fowler, MD, Associate Professor, Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX

Fredrick B. Hagemester, MD, Internist and Professor of Medicine, Department of Lymphoma/ Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Elias Jabbour, MD, Associate Professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Elisabet E. Manasanch, MD, Assistant Professor, Department of Lymphoma/Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Robert Orłowski, MD, PhD, Professor of Medicine, Department of Lymphoma/Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Michael Wang, MD, Professor of Medicine, Department of Lymphoma/Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

William G. Wierda, MD, Professor of Medicine, Department of Lymphoma/ Myeloma, Division of Cancer Medicine, University of Texas MD Anderson Cancer Center, Houston, TX

**Registration Fee**

Registration fee partially covers continental breakfast, lunch and syllabus book

	<b>Early Registration Fee (Up to 6/30/17) (7/1/17 to 7/7/17)</b>	<b>Discounted Registration Fee (7/8/17 to 7/15/17)</b>	<b>Regular Registration Fee</b>
<input type="checkbox"/> Physicians	\$100.00	\$130.00	\$160.00
<input type="checkbox"/> Registered Nurses	\$75.00	\$95.00	\$115.00
<input type="checkbox"/> Nurse Practitioners	\$75.00	\$95.00	\$115.00
<input type="checkbox"/> Physician Assistants	\$75.00	\$95.00	\$115.00
<input type="checkbox"/> Pharmacists	\$75.00	\$95.00	\$115.00
<input type="checkbox"/> Fellows	\$75.00	\$95.00	\$115.00
<input type="checkbox"/> *Industry	\$350.00	\$400.00	\$450.00

\*Person(s) employed by for-profit organizations such as pharmaceutical and biotech companies, and financial institutions

Payment may be made:  MC       Visa       Discover       Check

Credit Card Number \_\_\_\_\_ Expiration Date \_\_\_\_\_

Name and address† \_\_\_\_\_ Email \_\_\_\_\_

Pharmacist e-profile NABP# \_\_\_\_\_ Pharmacist DOB (MMDD) \_\_\_\_\_

Signature \_\_\_\_\_

†as given on the monthly credit card statement

No refund. Substitution is allowed.

Register online at [www.cancernetus.com](http://www.cancernetus.com)

Please make checks payable to **CancerNet**. Mail checks to CancerNet, 860 Hebron Pkwy, Suite 1104, Lewisville, TX 75057

To reserve your place for the meeting, please complete the registration form and fax it 443-267-0016. For and questions please call Brian Waggoner at 972-459-5222 or E-mail: [brianw@cancernetus.com](mailto:brianw@cancernetus.com)

### **Physician Continuing Education**

#### **Accreditation Statement**

This activity has been planned and implemented in accordance with the accreditation requirements and the policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of A. Webb Roberts Center for CME of Baylor Scott & White Health and CancerNet. The A. Webb Roberts Center for CME of Baylor Scott & White Health is accredited by the ACCME to provide continuing medical education for physicians.

#### **Credit Designation**

The A. Webb Roberts Center for CME of Baylor Scott & White Health designates this educational activity for a maximum of 6.5 *AAMA PRA Category 1 Credit(s)*<sup>TM</sup>. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

### **Nursing Continuing Education**

#### **Accreditation Statement**

American Health Resources, Inc. is approved by the California Board of Registered Nursing, Provider # CEP 14254 and approved this program for 6.5 contact hours. Please check with licensing board to verify credits can be claimed in your state.

### **Pharmacist Continuing Education**

#### **Accreditation Statement**



American Health Resource is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

#### **Credit Designation**

This activity provides 6.5 contact hours (0.65CEUs) -Application based credits  
ACPE Universal Activity Number: 0280-9999-17-064-L01-P

#### **Participant Requirements for Credit (Nurses and Pharmacists):**

- Participants must fully attend all sessions as well as pass in a completed signature verification form (No partial credit will be given).
- Participants can earn Continuing Education credits for this program by logging onto the website <https://ce.ahrevents.com/> and completing the session evaluation form for sessions attended.
  - **Nurses:** After completion of the evaluation, certificate of credit can be printed.
  - **Pharmacists:** After completion of the activity evaluation, pharmacy education credit is automatically reported to CPE Monitor where a certificate of credit can be printed. Please allow up to 48 hours for credit to be available on the CPE Monitor.
    - \***Only Certificates of Credit issued from CPE Monitor are valid in the US**
    - \* **CPE Monitor will not accept credits after 60 days from the session date**
- All participant names will be checked against program attendance sheets for verification of attendance.

**Disclosure & Evaluation:** All participants will have the opportunity to evaluate the educational session and presenter as well as the ability to identify their future educational needs. Disclosure will be made on the day of the program regarding any interest or affiliation a speaker may have with a supporting organization.

**6<sup>th</sup> Annual Symposium on Current Strategies in the Treatment of Hodgkins Lymphoma, B-cell Lymphoma,  
Multiple Myeloma and Leukemia – Houston, TX – July 15, 2017**

<b>7:00 AM</b>	Breakfast and Registrations	
<b>7:55 AM</b>	Welcome and Introductions	Fredrick B. Hagemeister, MD
<b>HODGKIN LYMPHOMA (HL)</b>		
<b>8:00 AM</b>	Overview of Diagnosis and Novel Treatment Options in the Management of Hodgkin Lymphoma (HL)	TBD
<b>8:30 AM</b>	Overview of Immunotherapy Options for HL	Fredrick B. Hagemeister, MD
<b>NON-HODGKIN LYMPHOMA (B-CELL LYMPHOMA)</b>		
<b>9:00 AM</b>	Overview of Treatment Options for Diffuse Large Cell Lymphoma (DLCL)	Fredrick B. Hagemeister, MD
<b>9:30 AM</b>	Overview of Treatment Options for Follicular Lymphoma (FL)	Nathan Fowler, MD
<b>10:00 AM</b>	Panel Discussion and Case Presentation	Fredrick B. Hagemeister, MD/Nathan Fowler, MD
<b>10:15 AM</b>	BREAK	
<b>10:30 AM</b>	Overview of Treatment Options for Mantle Cell Lymphoma (MCL)	Michael Wang, MD
<b>11:00 AM</b>	Overview of Treatment Options for Chronic Lymphocytic Leukemia (CLL)	William Wierda, MD
<b>MULTIPLE MYELOMA</b>		
<b>11:30 AM</b>	An Overview on Systemic Therapy for Patients with Newly Diagnosed Active Multiple Myeloma (MM)	Elizabet Manasanch, MD
<b>12:00 PM</b>	Outline the Selection, Sequencing and/or Combination of Novel Therapies for Patients with Relapsed/ refractory MM	Robert Orłowski, MD
<b>12:30 PM</b>	Panel Discussion and Case Presentation	Michael Wang, MD/ William Wierda, MD/ Elizabet Manasanch, MD/ Robert Orłowski, MD
<b>12:45 PM</b>	LUNCH	
<b>LEUKEMIA (ALL, AML and CML)</b>		
<b>1:30 PM</b>	Novel Therapies for adolescents and young adults (AYA), Philadelphia-positive and Philadelphia-negative Relapsed/Refractory Patients with ALL	Elias Jabbour, MD
<b>2:00 PM</b>	How Gene-gene Co-occurrences and Compound Genotypes are Related to Novel Therapies Based Clinical Outcomes in Patients with AML	Jorge Cortes, MD
<b>2:30 PM</b>	BREAK	
<b>2:45 PM</b>	Response Assessment and Management of Tyrosine Kinase Inhibitors Resistance in the Management of Chronic Myelogenous Leukemia (CML)	Elias Jabbour, MD
<b>3:15 PM</b>	Understanding of Time-based Response Milestones and Monitoring in Patients with CML	Jorge Cortes, MD
<b>3:45 PM</b>	Panel Discussion and Case Presentation	Elias Jabbour, MD/Jorge Cortes, MD
<b>4:00 PM</b>	Closing Remarks and Adjourn	Fredrick B. Hagemeister, MD